Betahistine Dihydrochloride CAS 5579-84-0

Product Description:

Product Name: Betahistine dihydrochloride CAS NO: 5579-84-0                              

Synonyms:

N-methyl-2-pyridin-2-ylethanamine,dihydrochloride;

n-methyl-2-pyridineethanamindihydrochloride;

Methyl[2-(2-pyridyl)ethyl]amine 2HCl;

Chemical & Physical Properties:

Appearance: White to light yellow crystalline powder

Assay :≥99.0%

Density: 0.967 g/cm3

Boiling Point: 210.9℃ at 760 mmHg

Melting Point: 150-154℃

Flash Point: 96.7℃

Solubility: Very soluble in water, soluble in ethanol (96 per cent), practically insoluble in 2propanol.

Stability: Stable at room temperature in closed containers under normal storage and handling conditions.

Storage Condition: Keep container closed when not in use. Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

Safety Information:

RTECS: UT2969000

Safety Statements: S24/25

HS Code: 2933399090

WGK Germany: 3

Betahistine is most commonly used to treat the symptoms of Ménière's disease and vertigo. Vasodilator. Betahistine Dihydrochloride is a histamine H3 receptors inhibitor used as an antivertigo drug.Target: Histamine ReceptorBetahistine, a structural analogue of histamine with weak histamine H(1) receptor agonist and more potent H(3) receptor antagonist properties. Betahistine acts centrally by enhancing histamine synthesis within tuberomammillary nuclei of the posterior hypothalamus and histamine release within vestibular nuclei through antagonism of H(3) autoreceptors. Therapeutic effects of betahistine in vestibular disorders result from its antagonist properties at histamine H(3) receptors (H(3)Rs). On inhibition of cAMP formation and [(3)H]arachidonic acid release, betahistine behaved as a nanomolar inverse agonist and a micromolar agonist. After acute oral administration, Betahistine increased t-MeHA levels with an ED(50) of 2 mg/kg, a rightward shift probably caused by almost complete first-pass metabolism. Therapeutic effects of betahistine result from an enhancement of histamine neuron activity induced by inverse agonism at H(3) autoreceptors.

If you are interested in our products or have any questions, please feel free to contact us!

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.